Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
25 April 2023 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2023
(Commission File No. 001-40241)
LAVA Therapeutics N.V.
(Translation of registrant’s name into English)
Yalelaan 62
3584 CM Utrecht, The Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
LAVA Therapeutics, N.V.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| LAVA Therapeutics, N.V. |
| (Registrant) |
| | |
Date: April 24, 2023 | By: | /s/ Fred Powell |
| Fred Powell |
| Chief Financial Officer |
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Dec 2023 to Dec 2024
